A large clinical trial found that long-term treatment with Gamunex improves and maintains physical and mental component scores in patients with CIDP. Improvements were observed in all domains, including physical functioning, role-physical, social functioning, and mental health.
A novel intranasal influenza vaccine has elicited immune responses more than 20 times higher than traditional vaccines, using only half the standard antigen dose. The vaccine's nanoemulsion-based adjuvant system triggers unparalleled mucosal and systemic immunity without pro-inflammatory materials or cytokines.
A novel topical treatment for cold sores has demonstrated equivalent efficacy to oral systemic drugs without safety or toxicity concerns. The treatment, NB-001, speeds up healing of lesions by 1.3 days and is well-tolerated with no adverse events.
A novel topical therapy, NB-002, has demonstrated a unique approach to healing nail fungus by penetrating skin pores and diffusing through the skin surrounding the entire nail plate. The lotion has shown robust antifungal activity against all organisms causing nail fungus, including Trichophyton rubrum and Candida albicans.
A new topical lotion has shown high degree of safety and tolerability in treating toenail fungus. The treatment avoids systemic absorption, reducing risks of cardiac and liver toxicity associated with current oral medications.
Researchers found that rifaximin significantly improved disease activity in patients with Crohn's disease. The analysis of 8 patients showed a mean decrease in Harvey Bradshaw index of 7.1, indicating potential effectiveness as a treatment.
In two studies, Lichtenstein and colleagues found that Rifaximin relieved symptoms of SBBO and pouchitis in patients with Crohn's disease, scleroderma, and mixed connective tissue disorders. The antibiotic demonstrated complete remission of symptoms in most patients, with no adverse events reported.